Bhawna SIROHI

After completing her training in Medical Oncology at Tata Cancer Hospital, Mumbai, Dr Sorohi moved to the UK where she worked in several insititions including the prestigious The Royal Marsden NHS Foundation Trust for 10 years.

From October 2009 to June 2010 after returning from the UK she became, Director and Chief consultant of the Medical Oncology (Pan-Max) in the Max Cancer Centre, in New Delhi .
From July 2010 to April 2012 Dr Sirohi has then been the Head of Medical & Haemato-Oncology of the Artemis Cancer Centre, a 300-bedded tertiary care private hospital located in Gurgaon and Delhi, India where she develepoed a comprehensive modern cancer center

She is currently a Consultant Medical Oncologist in the GI & Breast Unit at Tata Memorial Centre in Mumbai

She is a member of several international scientific society such as the American Society of Clinical Oncology, the American Society of Haematology, the European School of Medical Oncology, the Early Breast Cancer Trialists Collaborative Group, the International Myeloma Foundation, EBMT, the European Haematology, the Indian Medical Association, ICON, the Indian Society of Medical and Paediatric Oncology
She is also the Editor of the Indian Journal of Medical and Paediatric Oncology (IJMPO) and Health Positive

Dr Sirohi has participated in the organisation of over 20 national or international medical events and has received many awards and distinctions including the Women’s Cancer Initiative award in 2011 for charity work through NICCI.

Dr Sirohi has set up NICCI- New India Cancer Charity Initiative to do clinical screening in villages in UP and also train Aaganwadi and ASHA workers in early signs of cancer and healthy lifestyle. As part of this, I also do cancer awareness talks within NCR in schools, colleges, corporate and resident welfare organisations.

She has been chief investigator and principal investigator for various clinical trials for patients with melanoma, GI, breast, head and neck cancer, myeloma or investing new drugs like bevacizumab, Sunitinib, Sorafenib, PTK787, STA-4783, pazopanib, desonumab leading the over 100 invited lectures, 20 oral presentations, 70 Peer-reviewed Papers, 14 book chapters & Reviews.